Cardlytics, Inc. (CDLX)
Cardlytics: Short-Term Headwinds Drive Long-Term Success
Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Cardlytics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Cardlytics, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Cardlytics (CDLX)
Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript
Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript
Cardlytics (CDLX) Reports Q3 Loss, Tops Revenue Estimates
Cardlytics (CDLX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.01 per share a year ago.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cardlytics, Inc. - CDLX
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
